Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Drug Resistance Assay Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for RHOB drug discovery and selectivity screening. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | RHOB Recombinant Protein (WT & Mutants) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. Suitable for nucleotide exchange assays. |
View RHOB Products |
| Gene Delivery | RHOB Promise-ORF / Lentivirus Full-length ORF (WT/G14V/T19N) for stable cell line construction and signaling studies. |
View RHOB Products |
| Benchmark Ab | Anti-RHOB Recombinant Antibody Recombinant positive control for Western Blot, IHC, and IP validation. |
View RHOB Products |
| Validator | RHOB siRNA Set For target knockdown verification in phenotypic and resistance assays. |
View RHOB Products |
| Related Target A | RHOA High-homology subfamily member (85% identity). Essential counter-screening target to ensure drug selectivity. |
View RHOA Products |
| Related Target B | EGFR RHOB regulates EGFR trafficking and degradation. Critical target in EGFR-TKI resistance bypass studies. |
View EGFR Products |
| Related Target C | KRAS RHOB modulates downstream signaling of KRAS. Vital for combination therapy research in KRAS-mutant cancers. |
View KRAS Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High Homology Off-Target Risks (RHOA/RHOC) | Sequence-verified, MS-confirmed recombinant RHOA, RHOB, and RHOC proteins available for rigorous selectivity profiling. |
| Intracellular Conformation Stability | Lentiviral vectors delivering WT and mutant (G14V/T19N) RHOB to preserve physiological intracellular conformation in live cell assays. |
| Lack of Reliable Reference Antibodies | Sequence-defined recombinant antibodies ensuring batch-to-batch consistency with zero hybridoma drift. |
| Assay Artifacts & False Positives | Validated siRNA pools included to confirm target-specific phenotypic rescue. |
Live RHOB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of RHOB is gaining significant traction as its role in tumor suppression, immune evasion, and drug resistance becomes clearer. Unlike its oncogenic homologs RHOA and RHOC, RHOB often acts as a tumor suppressor that is rapidly downregulated in aggressive cancers but transiently induced under cellular stress (such as DNA damage or hypoxia). The race for RHOB-targeted therapeutics is shifting from broad-spectrum prenylation inhibitors (like farnesyltransferase inhibitors) to highly selective small molecules, PROTACs, and combination therapies designed to exploit its role in receptor tyrosine kinase (RTK) trafficking.
As next-generation inhibitors targeting the EGFR and KRAS pathways face inevitable resistance, modulating RHOB expression or its nucleotide-binding state has emerged as a viable strategy to reverse resistance. The next wave of R&D is heavily focused on selective small-molecule binders that can differentiate RHOB from RHOA/C, requiring highly precise biochemical and cellular screening cascades.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (Inhibitors/Activators) | Academic Institutes, Biotech Startups | NSCLC, Triple-Negative Breast Cancer | Selectivity Assay (Need highly pure WT and mutant RHOB vs. RHOA/C proteins) |
| PROTAC / Degraders | Targeted Protein Degradation (TPD) Pioneers | Refractory Solid Tumors, Pancreatic Cancer | Ubiquitination & Binding Assays (Need stable, sequence-verified target proteins) |
| Gene Therapy / mRNA | RNA Therapeutics Developers | Metastatic Cancers (Restoring RHOB) | Expression & Knockdown Validation (Need high-titer Lentivirus and validated siRNA) |